

해외 바이오의약품 임상 현황 (2021.2.8~2021.2.14)

한국바이오의약품협회, 2021.2.16.
출처: ClinicalTrials.gov

○ 미국 9건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04580485	INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors	Ovarian Cancer Bladder Cancer Non Small Cell Lung Cancer Squamous Cell Carcinoma of Head and Neck Triple Negative Breast Cancer Castration Resistant Prostate Cancer	Drug: INCB106385 Drug: INCMGA00012	Incyte Corporation	Phase 1	——
NCT04387227	Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma	Drug: Carboplatin Biological: Pembrolizumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2	——
NCT04370301	Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	Primary Myelofibrosis Secondary Myelofibrosis	Drug: Cyclophosphamide Drug: JAK Inhibitor Drug: Fludarabine Biological: Recombinant Granulocyte Colony-Stimulating Factor Drug: Melphalan Drug: Mycophenolate Mofetil Procedure: Peripheral Blood Stem Cell Transplantation Drug: Tacrolimus Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2	——
NCT04359784	Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy	B-Cell Non-Hodgkin Lymphoma	Biological: Anakinra Biological: Axicabtagene Ciloleucel	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Sobi	Phase 2	——
NCT04303845	Erenumab For Treatment of Hemicrania Continua	Hemicrania Continua	Drug: Erenumab	Mayo Clinic	Phase 2	——
NCT04242264	Phase 2 Shigella Vaccine and Challenge	Immunisation Shigella Infection	Other: Placebo Biological: Shigella sonnei strain 53G Biological: WRSs2	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	——
NCT04614558	Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance	Monoclonal Gammopathy	Drug: Isatuximab	Columbia University Genzyme, a Sanofi Company	Phase 2	——
NCT04713592	Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement	Psoriasis	Drug: Risankizumab Drug: Placebo for Risankizumab	AbbVie	Phase 3	——
NCT04673357	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab Drug: Placebo	Janssen Research & Development, LLC	Phase 3	——

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04673357	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab Drug: Placebo	Janssen Research & Development, LLC	Phase 3	——

○ 독일 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04673357	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab Drug: Placebo	Janssen Research & Development, LLC	Phase 3	——

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04673357	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab Drug: Placebo	Janssen Research & Development, LLC	Phase 3	——